TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24506274

Group type: EXPERIMENTAL
Intervention: Anesthetic gel (5% lidocaine and 5% prilocaine) applied in the sulcus 5 minutes before the procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no anesthetic gel)
Number of subjects: 30
Study: 22633477

Group type: EXPERIMENTAL
Intervention: R2 sympathicotomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: R2-R3 sympathicotomy
Number of subjects: 100
Study: 20694407

Group type: EXPERIMENTAL
Intervention: 3 g/day of PUFAs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 18405951

Group type: EXPERIMENTAL
Intervention: Budesonide 200 mcg (for patients aged < 11 years) or 400 mcg once daily
Number of subjects: 7241

Group type: COMPARATOR
Intervention: Placebo plus usual asthma therapy
Number of subjects: 7241

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7241
Study: 15967303

Group type: EXPERIMENTAL
Intervention: Test product (Diphenidol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product (Diphenidol)
Number of subjects: 0
Study: 12053591

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (two puffs four times daily, 0.002 g/puff)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 10609422

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intensive clinical management (CM)
Number of subjects: 82
Study: 8519669

Group type: EXPERIMENTAL
Intervention: Primary treatment: debulking surgery followed by platinum-based chemotherapy
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Second debulking operation (randomised intervention)
Number of subjects: 362
Study: 29972393

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (PLT)
Number of subjects: 40
Study: 27663942

Group type: EXPERIMENTAL
Intervention: Open-label Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Open-label Atomoxetine (ATX) alone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo nonresponders treated with open-label Atomoxetine (ATX) for 10 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Treatment responders from the acute trial
Number of subjects: 117
Study: 24581813

Group type: EXPERIMENTAL
Intervention: Food safety map
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cooking class
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 22890209

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy matched controls)
Number of subjects: 28
Study: 20664284

Group type: EXPERIMENTAL
Intervention: Telmisartan-based therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: CCB-based therapy
Number of subjects: 100
Study: 17879428

Group type: EXPERIMENTAL
Intervention: Highest BMI quintile
Number of subjects: 89835

Group type: COMPARATOR
Intervention: Lowest BMI quintile
Number of subjects: 89835
Study: 15180174

Group type: EXPERIMENTAL
Intervention: Sigmasporin Microoral 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sandimmune Neoral 100 mg
Number of subjects: 24
Study: 12206354

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 50
Study: 11475748

Group type: EXPERIMENTAL
Intervention: Oxymatrine 600 mg per day intramuscularly
Number of subjects: 43

Group type: COMPARATOR
Intervention: General liver protective agents (vitamins)
Number of subjects: 43
Study: 7806419

Group type: EXPERIMENTAL
Intervention: Complement activating membranes (cuprophan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-activating membranes (polysulfone, polymethylmethacrylate, polyacrylonitrile)
Number of subjects: 0
Study: 2561379

Group type: EXPERIMENTAL
Intervention: Short‐lasting intensive immunosuppression (cyclophosphamide with ACTH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intramuscular ACTH
Number of subjects: 16
Study: 976003

Group type: EXPERIMENTAL
Intervention: Extended mastectomy
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 1580
Study: 30056743

Group type: EXPERIMENTAL
Intervention: Group-based vestibular rehabilitation for eight weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 65
Study: 28093896

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) and topical administration of tranexamic acid (TXA) (15 mg/kg i.v. and 1.0 g topically)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline both i.v. and topically)
Number of subjects: 100
Study: 24635496

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (400 μg) 4 hourly
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intracervical Foley catheter
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined use of intracervical Foley catheter and intravaginal misoprostol (400 μg) 4 hourly
Number of subjects: 90
Study: 23873542

Group type: EXPERIMENTAL
Intervention: Cool perches
Number of subjects: 1152

Group type: COMPARATOR
Intervention: High stocking density
Number of subjects: 1152
Study: 21572318

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ambu AuraOnce
Number of subjects: 208
Study: 19486375

Group type: EXPERIMENTAL
Intervention: PALS after treatment modelling intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (motivational rewards only)
Number of subjects: 53
Study: 16479769

Group type: EXPERIMENTAL
Intervention: Lingualized occlusion (LO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bilateral balanced occlusion (BBO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both LO and BBO
Number of subjects: 28
Study: 12635944

Group type: EXPERIMENTAL
Intervention: Polymyalgia rheumatica (PMR) patients
Number of subjects: 315

Group type: COMPARATOR
Intervention: Matched population controls
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mortality rate ratio (MRR) for PMR vs controls
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mortality from coronary heart disease or stroke
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mortality from cancer
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mortality from other causes
Number of subjects: 315
Study: 10632830

Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (relative risk reduction)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (absolute risk reduction)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control message briefly describing CRC screening methods
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (general)
Number of subjects: 399
Study: 8924192

Group type: EXPERIMENTAL
Intervention: Nortriptyline with IPT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nortriptyline with medication clinic (no IPT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo with IPT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo with medication clinic
Number of subjects: 72
Study: 1382793

Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 220
Study: 3877214

Group type: EXPERIMENTAL
Intervention: Cell Saver
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ultrafilter
Number of subjects: 27

Group type: COMPARATOR
Intervention: Retrospective Control
Number of subjects: 27
Study: 29681145

Group type: EXPERIMENTAL
Intervention: Perception of risk of drinking alcohol frequently
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Perception of risk of getting drunk
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Males, 12 years or younger
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Good relationship with mothers
Number of subjects: 3365
Study: 28002714

Group type: EXPERIMENTAL
Intervention: Hypothermia (32 to 34°C for 24 hours)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 270
Study: 24628736

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT 10 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 22835900

Group type: EXPERIMENTAL
Intervention: Biocompatible PD fluids (neutral-pH, low glucose degradation product 1.5% glucose solution; 1.1% amino acid solution; 7.5% icodextrin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional PD fluid
Number of subjects: 150
Study: 20644121

Group type: EXPERIMENTAL
Intervention: AIDA-2000 treatment including anthracycline-based consolidation and all-trans retinoic acid (ATRA) for 15 days during each consolidation.
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: AIDA-2000 treatment for high-risk patients including anthracycline-based consolidation and ATRA.
Number of subjects: 636

Group type: COMPARATOR
Intervention: AIDA-0493 treatment including cytarabine-containing regimens for high-risk patients.
Number of subjects: 636

Group type: COMPARATOR
Intervention: AIDA-0493 treatment including cytarabine-containing regimens for low/intermediate-risk patients.
Number of subjects: 636
Study: 18753119

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Interviewer-administered questionnaire (IAQ)
Number of subjects: 180
Study: 15878048

Group type: EXPERIMENTAL
Intervention: Ecologically based family therapy (EBFT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 124
Study: 12553397

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5% garlic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.2% tea tree oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 30
Study: 9607056

Group type: EXPERIMENTAL
Intervention: Five-valent pneumococcal conjugate vaccine (PCV); three doses separated by two months; types 6B, 14, 18C, 19F, and 23F
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline placebo; three doses
Number of subjects: 41
Study: 7634946

Group type: EXPERIMENTAL
Intervention: Duodenum-preserving resection of the head of the pancreas (DPRHP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Whipple procedure (PD)
Number of subjects: 43
Study: 2096747

Group type: EXPERIMENTAL
Intervention: Low dose atracurium/lidocaine combination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 40
Study: 509932

Group type: EXPERIMENTAL
Intervention: Baracaide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Swarfega
Number of subjects: 0

Group type: COMPARATOR
Intervention: Go‐Jo
Number of subjects: 0
Study: 31426362

Group type: EXPERIMENTAL
Intervention: ω3‐PUFA alone (800 mg DHA and 225 mg EPA daily)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus placebo
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Combined ω3‐PUFA and multidomain intervention
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1680
Study: 30246185

Group type: EXPERIMENTAL
Intervention: Fo3 (fixed-on-3) implants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fo4 (fixed-on-4) implants
Number of subjects: 48
Study: 28445193

Group type: EXPERIMENTAL
Intervention: 0.5% R348
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.2% R348
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% R348, 0.2% R348, Vehicle
Number of subjects: 30
Study: 25636332

Group type: EXPERIMENTAL
Intervention: Study intervention arm
Number of subjects: 14

Group type: COMPARATOR
Intervention: Contact-time comparison intervention arm
Number of subjects: 14
Study: 23895820

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VitD3) supplementation, 2,000 IU oral daily for 6 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VitD3) supplementation
Number of subjects: 101
Study: 20799388

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Conventional Glucose Monitoring (Standard Care Group)
Number of subjects: 671
Study: 19075203

Group type: COMPARATOR
Intervention: Surgery (primarily decompressive laminectomy for stenosis)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Surgery (decompressive laminectomy with fusion for degenerative spondylolisthesis)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Nonoperative care
Number of subjects: 634
Study: 16779534

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14684758

Group type: EXPERIMENTAL
Intervention: Asian ginseng (0, 1, 2, and 3 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 22
Study: 10871810

Group type: EXPERIMENTAL
Intervention: Neuromotor rehabilitative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stabilometric platform 'BIOGP'
Number of subjects: 0
Study: 9180065

Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Flexibility exercises and relaxation therapy for 12 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise after crossover from flexibility treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Supervised exercise treatment
Number of subjects: 66
Study: 8466022

Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g/250 mL normal saline)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (250 mL normal saline)
Number of subjects: 36
Study: 3889875

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30959915

Group type: EXPERIMENTAL
Intervention: Suboptimal intake of dietary fiber
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Suboptimal intake of saturated fatty acids (SFA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Suboptimal intake of mono-unsaturated fatty acids (MUFA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Suboptimal intake of poly-unsaturated fatty acids (PUFA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Suboptimal protein intake
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Micronutrient inadequacy for vitamin D
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Micronutrient inadequacy for thiamine
Number of subjects: 157
Study: 28340145

Group type: EXPERIMENTAL
Intervention: NKTR-181 (100 mg, 200 mg, 400 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NKTR-181 (400 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oxycodone (40 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NKTR-181
Number of subjects: 42
Study: 26678983

Group type: EXPERIMENTAL
Intervention: One-week informed consent information training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study: 26135957

Group type: EXPERIMENTAL
Intervention: Three doses of SCREAM Theater intervention
Number of subjects: 1390

Group type: COMPARATOR
Intervention: One dose of SCREAM Theater intervention
Number of subjects: 1390
Study: 22773673

Group type: EXPERIMENTAL
Intervention: Mini-screw implant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transpalatal arch
Number of subjects: 30
Study: 20237760

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18554236

Group type: EXPERIMENTAL
Intervention: GI-Mentor II simulator training (5 hours) plus bedside training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-simulator group (bedside training only)
Number of subjects: 20
Study: 16515105

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine, 1 ml (30 mg) of ketorolac and 9 ml of saline intra-articularly (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 ml of intra-articular saline and 10 ml of 0.25% bupivacaine (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 20 ml of intra-articular saline (Group A)
Number of subjects: 90
Study: 14527527

Group type: EXPERIMENTAL
Intervention: Combination treatment with sertraline and cognitive-behavior therapy (CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 10
Study: 10515020

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham control (n = 16)
Number of subjects: 31
Study: 8720019

Group type: EXPERIMENTAL
Intervention: Short message
Number of subjects: 3826

Group type: COMPARATOR
Intervention: Handwritten envelopes and machine-printed labels
Number of subjects: 3826

Group type: COMPARATOR
Intervention: Formal invitation, business letter with inside name and address, business letter without recipient's name and address
Number of subjects: 3826
Study: 3046626

Group type: EXPERIMENTAL
Intervention: metoprolol (M) 200 mg SR qd
Number of subjects: 143

Group type: COMPARATOR
Intervention: low-Na/high-K salt (S) 2 g bid
Number of subjects: 143
Study: 30654882

Group type: COMPARATOR
Intervention: Combination of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Number of subjects: 1448

Group type: COMPARATOR
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 1448
Study: 28882385

Group type: EXPERIMENTAL
Intervention: Vibrating mesh (VM) with 5000 μg salbutamol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Jet nebulizers (JN) with 5000 μg salbutamol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with AeroChamber Vent (MDI-AV) with 1600 μg salbutamol
Number of subjects: 36
Study: 25804100

Group type: EXPERIMENTAL
Intervention: Unloaded slow breathing training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Loaded slow breathing training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 20
Study: 24273930

Group type: EXPERIMENTAL
Intervention: Urtica dioica leaf extract (500 mg capsule every 8 hours for 3 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20467757

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg i.v. bolus 30 min before TMZ)
Number of subjects: 33
Study: 18456877

Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA) assessments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper assessments
Number of subjects: 0
Study: 21874971

Group type: EXPERIMENTAL
Intervention: In-situ simulation training
Number of subjects: 3

Group type: COMPARATOR
Intervention: TeamSTEPPS didactic training program
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study: 16220085

Group type: EXPERIMENTAL
Intervention: NFV + RTV + ddI
Number of subjects: 41

Group type: COMPARATOR
Intervention: NFV + NVP + d4T
Number of subjects: 41
Study: 12239424

Group type: EXPERIMENTAL
Intervention: Seresis (antioxidative combination containing carotenoids, vitamins C and E, selenium, and proanthocyanidins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seresis
Number of subjects: 0
Study: 9570193

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: NASCET-eligible patients
Number of subjects: 231
Study: 7923235

Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) treatment, initial dose of 10 mg/kg per day progressively increased up to a maximum of 140 mg/kg per day, in addition to conventional concomitant therapy.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment
Number of subjects: 69
Study: 3292753

Group type: EXPERIMENTAL
Intervention: Preoperative diflunisal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative placebo
Number of subjects: 50
Study: 12410546

Group type: EXPERIMENTAL
Intervention: valepotriates (mean daily dose: 81.3 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: diazepam (mean daily dose: 6.5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 30205353

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Somatization
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Clinical symptoms
Number of subjects: 1241
Study: 25863790

Group type: EXPERIMENTAL
Intervention: Brief parenting discussion group (n=45)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlist control group (n=40)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intervention group (n=45)
Number of subjects: 85
Study: 25106708

Group type: EXPERIMENTAL
Intervention: PLIF with porous ceramic corundum implants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Decompression by fenestration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (PLIF and decompression)
Number of subjects: 100
Study: 22131290

Group type: EXPERIMENTAL
Intervention: Nocturnal temperature controlled laminar airflow (TLA)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 20171235

Group type: EXPERIMENTAL
Intervention: Active participants performing the vigilance tasks (difficult and easy versions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Easier vigilance task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More difficult vigilance task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-work control group
Number of subjects: 0